WO 2005/023812 PCT/EP2004/052006

25 CLAIMS

1. A compound according to general formula I, or a pharmaceutically acceptable salt thereof,

formula l

wherein:

R1, R2 and R3 are each independently selected from H, alkyl, F and Cl; and R4 is selected from formulae II, III and IV:

10

15

5

- 2. A compound according to claim 1, selected among the group consisting of:
- 4-(3,5-Dihydroxy-benzyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-(3,5-Dihydroxy-benzyl)-piperazine-1-carboxylic acid 2,6-dimethyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-(3,5-Dihydroxy-benzyl)-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;

WO 2005/023812 PCT/EP2004/052006

- 4-(3,5-Dihydroxy-benzyl)-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-(3-Dimethylcarbamoyl-benzyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; and
- 4-(3-Dimethylthiocarbamoyl-benzyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide.
- 3. A pharmaceutical composition comprising a compound according to claim 1 or 2 as an active agent.
- 4. A pharmaceutical composition according to claim 3, further comprising a
 pharmaceutical acceptable adjuvant, diluent or carrier.
 - 5. A pharmaceutical composition according to claim 3 or 4, formulated as a tablet or capsule for oral administration.
- 6. A pharmaceutical composition according to any of the claims 3 5 for treatment of a disorder chosen among sexual disorders such as male erectile dysfunction, ejaculatory disorders and female sexual dysfunction; cancer of the prostate, breast, ovary and bones; osteoporosis; benign prostatic hyperplasia; post-partum bleeding and depression.
 - 7. A pharmaceutical composition according to claim 6 for treatment of male erectile dysfunction.
 - 8. The use of a compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, for the for treatment of a disorder chosen among sexual disorders such as male erectile dysfunction, ejaculatory disorders and female sexual dysfunction; cancer of the prostate, breast, ovary and bones; osteoporosis; benign prostatic hyperplasia; post-partum bleeding and depression.
- 9. The use of a compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, to induce labour or delivery of the placenta, to decrease

10

5

25

30

WO 2005/023812 PCT/EP2004/052006

27

arterial blood pressure, to decrease exaggerated responses to stress or to increase the nociceptive threshold.